← All trials
NCT05549726
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Sep 22, 2022
- Last posted
- Oct 10, 2022
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- ViiV HealthcareCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)Collaborator
- University of PittsburghCollaborator
- Kenya Medical Research InstituteCollaborator
- Makerere UniversityCollaborator
- Makerere UniversityOverall official - principal investigator
- University of California, BerkeleyCollaborator
- University of California, BerkeleyOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Infectious Disease Institute, Kampala, UgandaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.